The diabetes and weight‑loss drug market has entered 2026 with extraordinary momentum, building on the explosive growth seen throughout 2025.
With GLP‑1 and next‑generation obesity drugs gaining traction across the U.S. and globally, investors are now looking toward the companies best positioned to benefit from this acceleration. Here are seven stocks with clear catalysts and strong pipelines for 2026.
This post originally appeared at U.S. News & World Report.